Drug intelligence / Profile preview

DPX-103

Development stage: Unknown
Lead developer: DAMONA Pharmaceuticals
Modality: Small Molecules

Overview

DPX-103 is a small molecule chemical drug developed by Damona Pharmaceuticals. It is currently in preclinical development, with no disclosed active indications or detailed mechanism of action publicly available as of June 2025. The drug is part of Damona Pharmaceuticals' pipeline focused on central nervous system disorders and cognitive symptoms, but specific targets, mechanisms, or disease areas for DPX-103 have not been published. No clinical trials or regulatory approvals are reported for this compound at this time[1][2][4][6].

Beyond the preview

Go deeper on DPX-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPX-103.

Explore the full profile